Drugs / IL-2 secreting and hCL4OL-expressing autologous B-CLL cells
IL-2 secreting and hCL4OL-expressing autologous B-CLL cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00224354 | Sep 2005 → Dec 2009 | B-cell chronic lymphocytic leukemia | Baylor College of Medicine | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-2 secreting and hCL4OL-expressing autologous B-CLL cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00224354 ↗ |
| Modality | Cell therapy | “autologous leukemic cells modified ex vivo” NCT00224354 ↗ |
| Route | Subcutaneous | “six subcutaneous injections” NCT00224354 ↗ |